申请人:NAZARE Mark
公开号:US20090069565A1
公开(公告)日:2009-03-12
The present invention relates to compounds of formula I,
in which R
0
; R
1
; R
2
; R
3
; R
4
; R
5
; R
6
; R
7
; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.
本发明涉及式I的化合物,其中R0; R1; R2; R3; R4; R5; R6; R7; Q; V,G和M具有声明中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用,例如适用于治疗和预防心血管疾病,如血栓栓塞性疾病或再狭窄。它们是血凝酶酶因子Xa(FXa)和/或因子VIIa(FVIIa)的可逆抑制剂,并且通常可以应用于存在因子Xa和/或因子VIIa不良活性的情况,或者治疗或预防需要抑制因子Xa和/或因子VIIa的情况。此外,本发明还涉及制备式I化合物的方法,它们的用途,特别是作为治疗上述疾病的药物以及包含它们的制药制剂。